Literature DB >> 12355476

Predictors of infection in rheumatoid arthritis.

Michele F Doran1, Cynthia S Crowson, Gregory R Pond, W Michael O'Fallon, Sherine E Gabriel.   

Abstract

OBJECTIVE: Patients with rheumatoid arthritis (RA) have been shown to have an increased susceptibility to the development of infections. The exact causes of this increased risk are unknown, but may relate to immunologic disturbances associated with the disease or to the immunosuppressive effects of agents used in its treatment. This study was undertaken to identify predictors of serious infections among patients with RA. Identification of such factors is the necessary first step in reducing the excess risk of infection in RA.
METHODS: Members of a population-based incidence cohort of Rochester, Minnesota residents ages >or=18 years, who had been diagnosed with RA between 1955 and 1994, were followed up longitudinally through their complete medical records until January 1, 2000. We examined potential risk factors for the development of all objectively confirmed (by microbiology or radiology) infections and for infections requiring hospitalization. Potential risk factors included RA severity measures (rheumatoid factor positivity, elevated erythrocyte sedimentation rate, extraarticular manifestations of RA, and functional status), comorbidities (diabetes mellitus, alcoholism, and chronic lung disease), and other risk factors for infection (presence of leukopenia, smoking). Predictors were identified using multivariate time-dependent Cox proportional hazards modeling.
RESULTS: The 609 RA patients in the cohort had a total followup time of 7,729.7 person-years (mean 12.7 years per patient). A total of 389 patients (64%) had at least 1 infection with objective confirmation, and 290 (48%) had at least 1 infection requiring hospitalization. Increasing age, presence of extraarticular manifestations of RA, leukopenia, and comorbidities (chronic lung disease, alcoholism, organic brain disease, and diabetes mellitus), as well as use of corticosteroids, were strong predictors of infection (P < 0.004) in both univariate and multivariate analyses. Notably, use of disease-modifying antirheumatic drugs was not associated with increased risk of infection in multivariate analyses, after adjustment for demographic characteristics, comorbidities, and disease-related variables.
CONCLUSION: We identified a number of strong predictors of infections in a population-based cohort of patients with RA. These results can be used to prospectively identify high-risk patients, who may benefit from closer followup and implementation of preventive strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355476     DOI: 10.1002/art.10529

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  164 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; M Dougados; P Emery; A Gibofsky; A F Kavanaugh; E C Keystone; L Klareskog; A S Russell; L B A van de Putte; M H Weisman; A F Kavenaugh
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 3.  Perioperative care for patients with rheumatic diseases.

Authors:  Bharath M Akkara Veetil; Tim Bongartz
Journal:  Nat Rev Rheumatol       Date:  2011-11-15       Impact factor: 20.543

Review 4.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

5.  Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study.

Authors:  Andrew D Wiese; Marie R Griffin; C Michael Stein; Edward F Mitchel; Carlos G Grijalva
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

6.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis.

Authors:  R M Fleischmann; J Tesser; M H Schiff; J Schechtman; G-R Burmester; R Bennett; D Modafferi; L Zhou; D Bell; B Appleton
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

7.  Prevalence and clinical characteristics of tuberculosis in rheumatoid arthritis patients.

Authors:  Fadoua Allali; Hanane Rkain; Afaf Faik; Selma El Hassani; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2004-12-03       Impact factor: 2.980

8.  Multiple extra-articular manifestations are associated with poor survival in patients with rheumatoid arthritis.

Authors:  C Turesson; R L McClelland; T J H Christianson; E L Matteson
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

9.  Molecular diagnosis of opportunistic pericardial infection in a patient treated with adalimumab: the role of next-generation sequencing.

Authors:  Stefano Poli; Manola Comar; Roberto Luzzati; Gianfranco Sinagra
Journal:  BMJ Case Rep       Date:  2016-08-29

Review 10.  Tumor necrosis factor inhibitors and infection complications.

Authors:  Monica Crawford; Jeffrey R Curtis
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.